Coordinated AR and microRNA regulation in prostate cancer

被引:14
作者
Eringyte, Ieva [1 ]
Losada, Joanna N. Zamarbide [1 ]
Powell, Sue M. [1 ]
Bevan, Charlotte L. [1 ]
Fletcher, Claire E. [1 ]
机构
[1] Imperial Coll London, Hammersmith Hosp, Dept Surg & Canc, Imperial Ctr Translat & Expt Med, London, England
关键词
MicroRNA; Androgen receptor; Androgen; Prostate cancer; Hormone; Non-coding RNA; ANDROGEN RECEPTOR EXPRESSION; LONG NONCODING RNA; TUMOR-SUPPRESSOR; SPLICE VARIANTS; CIRCULATING MICRORNAS; ALTERNATIVE POLYADENYLATION; INHIBITS PROLIFERATION; TARGETED THERAPY; MESSENGER-RNA; GROWTH;
D O I
10.1016/j.ajur.2020.06.003
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
The androgen receptor (AR) remains a key driver of prostate cancer (PCa) progression, even in the advanced castrate-resistant stage, where testicular androgens are absent. It is therefore of critical importance to understand the molecular mechanisms governing its activity and regulation during prostate tumourigenesis. MicroRNAs (miRs) are small similar to 22 nt noncoding RNAs that regulate target gene, often through association with 30 untranslated regions (3'UTRs) of transcripts. They display dysregulation during cancer progression, can function as oncogenes or tumour suppressors, and are increasingly recognised as targets or regulators of hormonal action. Thus, understanding factors which modulate miRs synthesis is essential. There is increasing evidence for complex and dynamic bi-directional cross-talk between the multi-step miR biogenesis cascade and the AR signalling axis in PCa. This review summarises the wealth of mechanisms by which miRs are regulated by AR, and conversely, how miRs impact AR's transcriptional activity, including that of AR splice variants. In addition, we assess the implications of the convergence of these pathways on the clinical employment of miRs as PCa biomarkers and therapeutic targets. (C) 2020 Editorial Office of Asian Journal of Urology. Production and hosting by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
引用
收藏
页码:233 / 250
页数:18
相关论文
共 182 条
  • [1] [Anonymous], 2007, ENDOCR REV, DOI DOI 10.1210/ER.2007-0019
  • [2] [Anonymous], 2014, ONCOL REP, DOI DOI 10.3892/OR.2013.2810
  • [3] [Anonymous], 2017, ONCOGENE, DOI DOI 10.1038/ONC.2016.185
  • [4] [Anonymous], 2016, CANCER RES, DOI DOI 10.1158/0008-5472.CAN-15-3339
  • [5] [Anonymous], 2011, CANCER RES, DOI DOI 10.1158/0008-5472.CAN-10-2421
  • [6] [Anonymous], 2016, ONCOTARGET, DOI DOI 10.18632/ONCOTARGET.12241
  • [7] [Anonymous], 2015, CANCER RES, DOI DOI 10.1158/0008-5472.CAN-14-0795
  • [8] [Anonymous], 2014, ONCOTARGET
  • [9] [Anonymous], 2017, BIOCHEM BIOPH RES CO, DOI DOI 10.1016/J.BBRC.2016.12.045
  • [10] [Anonymous], 2019, ONCOGENE, DOI DOI 10.1038/S41388-019-0768-8